FDA’s Lykos Rejection Delays—But Doesn’t Stop—Psychedelic Therapies

Psychedelic drug developers are undeterred by the FDA’s Complete Response Letter for the company’s MDMA therapy for PTSD, and experts expect Lykos will ultimately obtain approval.